#<p> This refers to the number of patients switching treatment due to specific toxicity specified on the row. % was determined by dividing the number of patients switching treatment due to a specific toxicity by the total number of patients with that particular toxicity in question.</p>§<p> n(%) n refers to the number of patients who experienced specific toxicity and the % refers to number of patients with toxicity divided by the total number of patients starting ART which was 4,039. An individual patient may experience more than one toxicity during follow up and may experience a specific toxicity more than one episode during follow up.</p><p>Frequencies of specific toxicities and treatment switches among Ghanaian cohort on long-term cART.<...
<p>Frequency of each type of exposure in healthy volunteers and in patients group according to their...
<p>Percentage of adverse drug events with number of co-medication per age category during 2000–2009....
<p>n: number of resistance tests (first test/patient per year) presenting with mutations associated ...
<p>Number and percentages of subjects showing adverse events after administration of drugs in differ...
<p>The frequency of late toxicities for the three groups [No. of patient (%)].</p
<p>The frequency of acute toxicities for the three groups [No. of patient (%)].</p
<p>N: Number of subjects inoculated; n: Number of subjects with adverse events; E: Number of adverse...
Treatment-related adverse events occurring in ≥1% of the total population (SS).</p
<p>N, number of patients; n, number of events; %, percentage based on N = 275.</p
<p>*The preferred adverse event term used for “CF exacerbation” was “cystic fibrosis.”</p><p>A patie...
<p>The population number used as the denominator to obtain the proportion in the y-axis was the numb...
<p>Toxicity rates of cART modification per 100 person years for individual antiretroviral regimen.</...
<p>Proportionate distribution (per 1000 admissions) of ten leading causes of death in patients aged ...
<p>Number of local solicited adverse events during week 1 and 2 for each dose group (n = 12 per grou...
<p>Numbers of Subjects Who Changed From Initial High Risk to Low Risk and From Initial Low Risk to H...
<p>Frequency of each type of exposure in healthy volunteers and in patients group according to their...
<p>Percentage of adverse drug events with number of co-medication per age category during 2000–2009....
<p>n: number of resistance tests (first test/patient per year) presenting with mutations associated ...
<p>Number and percentages of subjects showing adverse events after administration of drugs in differ...
<p>The frequency of late toxicities for the three groups [No. of patient (%)].</p
<p>The frequency of acute toxicities for the three groups [No. of patient (%)].</p
<p>N: Number of subjects inoculated; n: Number of subjects with adverse events; E: Number of adverse...
Treatment-related adverse events occurring in ≥1% of the total population (SS).</p
<p>N, number of patients; n, number of events; %, percentage based on N = 275.</p
<p>*The preferred adverse event term used for “CF exacerbation” was “cystic fibrosis.”</p><p>A patie...
<p>The population number used as the denominator to obtain the proportion in the y-axis was the numb...
<p>Toxicity rates of cART modification per 100 person years for individual antiretroviral regimen.</...
<p>Proportionate distribution (per 1000 admissions) of ten leading causes of death in patients aged ...
<p>Number of local solicited adverse events during week 1 and 2 for each dose group (n = 12 per grou...
<p>Numbers of Subjects Who Changed From Initial High Risk to Low Risk and From Initial Low Risk to H...
<p>Frequency of each type of exposure in healthy volunteers and in patients group according to their...
<p>Percentage of adverse drug events with number of co-medication per age category during 2000–2009....
<p>n: number of resistance tests (first test/patient per year) presenting with mutations associated ...